Everything below concerns freeze-thaw cycle. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-19. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
| Property | Value | Notes |
|---|---|---|
| Dry storage temperature | -20 C or below | Sealed, desiccated, protected from light |
| Solution stability | Hours to days at 2-8 C | Depends on buffer and microbial load |
| Preferred pH range | Near neutral to slightly acidic | Alkaline pH accelerates hydrolysis |
| Main degradation routes | Hydrolysis and deamidation | No cysteine or methionine in sequence |
| Identity confirmation | Electrospray mass spectrometry | Observed mass compared with 751.9 Da |
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Seinen Untergebenen Gambit beauftragte Sinister, die Marauders, eine Gruppe von Mutanten und Söldnern, bei einem Angriff auf die Morlocks anzuführen, eine Schicksalsgemeinschaft von körperlich deformierten oder entstellten Mutanten, die sich in der Kanalisation New Yorks vor der Welt versteckten; das berüchtigte Mutant Massacre. Sinister war auch verantwortlich für das Klonen von Jean Grey, woraus später Madelyne Pryor werden sollte. Ebenso zeichnete er für das Legacy-Virus verantwortlich, das darauf programmiert war, Mutanten zu infinzieren und zu töten. Mister Sinister hat von Apocalypse u. a. eine enorm gesteigerte Kraft, Heilung und Lebensspanne erhalten sowie durch spätere Selbstversuche die Fähigkeiten der Telekinese, Telepathie, Gestaltwandeln und Energiestrahlen aus seinen Händen zu „schießen“. Mr. Sinisters erster Auftritt war in Uncanny X-Men # 221 (September 1987). Andere Medien:
In X-Men 2 erscheint Mr. Sinisters Name auf einem Computer-Bildschirm. In X-Men: Apocalypse sieht man in einer Post-Credit-Szene eine Gruppe von Männern, die im Auftrag von Mr. Sinisters Firma Essex Corporation eine Blutprobe von Wolverine sichern.
=== Mystique === Raven Darkholme ist, als Mystique, eine Mutantin mit gestaltwandlerischer Fähigkeit, verlangsamter Alterung und erhöhter Regenerationsfähigkeit. Obwohl ihre Hautfarbe von Natur tiefblau ist, kann Mystique jeden Menschen in Sekundenschnelle in Aussehen und Sprache imitieren. Sie ist eine hervorragende Nahkämpferin, die mit diversen Waffen umzugehen weiß, außerdem ist sie eine brillante Hackerin. Mystique ist die Ziehmutter von Rogue und die leibliche Mutter von Nightcrawler; auch der Präsidentschaftskandidat Graydon Creed ist ihr Sohn. Sie war Anführerin der zweiten Inkarnation der „Bruderschaft der bösen Mutanten“ (Brotherhood of Evil Mutants), die später eine Zeit lang als Spezialeingreiftruppe unter dem Namen Freedom Force für die US-Regierung arbeitete. Ihr erster Auftritt war in Ms. Marvel # 16 (Mai 1978). Andere Medien:
In den ersten drei X-Men-Kinofilmen (X-Men, X-Men 2 und X-Men: Der letzte Widerstand) sowie in Avengers: Doomsday wird Mystique von Rebecca Romijn gespielt. In X-Men: Erste Entscheidung, X-Men: Zukunft ist Vergangenheit, X-Men: Apocalypse und X-Men: Dark Phoenix wird sie von Jennifer Lawrence verkörpert.
Sources: de.wikipedia.org
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.
Hydrolysis of peptide bonds and deamidation of arginine and proline residues are the main degradation routes. Alkaline pH and higher temperatures accelerate both processes. Buffered, near-neutral solutions stored cold generally degrade more slowly than unbuffered ones.
Reverse-phase chromatography gives the clearest single view of related impurities and truncated sequences. Mass spectrometry then confirms that the main peak carries the expected mass. Neither test detects enantiomeric impurities, which require a separate chiral assay.
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.